Orphazyme A/S
CSE:ORPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Onex Corp
TSE:5987
|
JP |
|
A
|
Ahresty Corp
TSE:5852
|
JP |
|
A
|
Azkoyen SA
LSE:0DOG
|
ES |
|
C
|
CardioComm Solutions Inc
OTC:EKGGF
|
CA |
Orphazyme A/S
Total Equity
Orphazyme A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orphazyme A/S
CSE:ORPHA
|
Total Equity
kr14.2m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
28%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr14.8B
|
CAGR 3-Years
163%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Equity
$15.8m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€162.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr12.9B
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
|
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
See Also
What is Orphazyme A/S's Total Equity?
Total Equity
14.2m
DKK
Based on the financial report for Dec 31, 2023, Orphazyme A/S's Total Equity amounts to 14.2m DKK.
What is Orphazyme A/S's Total Equity growth rate?
Total Equity CAGR 5Y
-48%
Over the last year, the Total Equity growth was -65%. The average annual Total Equity growth rates for Orphazyme A/S have been -72% over the past three years , -48% over the past five years .
